

At page 34, line 18, delete “(Attorney Docket No. VDB98-01).”

In the claims:

Kindly cancel claims 1-47 and 49-67, and amend claim 48 as follows.

Q2
48. (Amended) A method of detecting *Chlamydia* [chlamydial elementary bodies] in a sample, said method comprising performing on the sample an antigen capture assay using an antibody that specifically binds to a peptide having a sequence consisting essentially of SEQ ID NO: 93; SEQ ID NO: 96; SEQ ID NO: 97; SEQ ID NO: 100; or SEQ ID NO: 101 [directed against MOMP or the peptides described in Figures 3, 4, and 5].

Kindly add new claims 68-75 as follows.

Q3
68. A method for detecting *Chlamydia* in a sample, said method comprising the steps of:

a) contacting said sample with an antibody that specifically binds to a peptide having a sequence consisting essentially of SEQ ID NO: 93; SEQ ID NO: 96; SEQ ID NO: 97; SEQ ID NO: 100; or SEQ ID NO: 101; and

b) detecting the binding of said antibody to a sample component of said sample, wherein binding of said antibody indicates the presence of *Chlamydia* in said sample.

69. The method of claim 68, wherein said antibody specifically binds to a peptide having a sequence consisting essentially of SEQ ID NO: 93 or SEQ ID NO: 97, and the binding of said antibody to said sample component indicates that said *Chlamydia* is *Chlamydia pneumoniae*.

AB
cont
X 70. The method of claim 68, wherein said antibody specifically binds to a peptide having a sequence consisting essentially of SEQ ID NO: 96 or SEQ ID NO: 100, and the binding of said antibody to said sample component indicates that said *Chlamydia* is *Chlamydia psittaci*.

71. A method for detecting the presence of *Chlamydia* in a sample, said method comprising the steps of:

a) immobilizing said sample onto a substrate;

b) contacting said sample with an antibody that specifically binds to a peptide having a sequence consisting essentially of SEQ ID NO: 93; SEQ ID NO: 96; SEQ ID NO: 97; SEQ ID NO: 100; or SEQ ID NO: 101, wherein said antibody becomes immobilized if said sample contains *Chlamydia*; and

c) detecting the presence of immobilized antibody, wherein the presence of immobilized antibody indicates the presence of *Chlamydia* in said sample.

72. The method of claim 71, wherein said antibody specifically binds to a peptide having a sequence consisting essentially of SEQ ID NO: 93 or SEQ ID NO: 97, and the presence of immobilized antibody indicates that said *Chlamydia* is *Chlamydia pneumoniae*.

Q3 cent
X 73. The method of claim 71, wherein said antibody specifically binds to a peptide having a sequence consisting essentially of SEQ ID NO: 96 or SEQ ID NO: 100, and the presence of immobilized antibody indicates that said *Chlamydia* is *Chlamydia psittaci*.

74. A substantially pure polypeptide having a sequence consisting essentially of SEQ ID NO: 93; SEQ ID NO: 96; SEQ ID NO: 97; SEQ ID NO: 100; or SEQ ID NO: 101.

75. An antibody that specifically binds to a peptide having a sequence consisting essentially of SEQ ID NO: 93; SEQ ID NO: 96; SEQ ID NO: 97; SEQ ID NO: 100; or SEQ ID NO: 101.--


Support for new claims 68-75 is found at pages 67-73 of the specification. No new matter has been added by this amendment.

Conclusion

Enclosed is a copy of the petition to extend the period for replying to the Examiner's action in parent application serial no. 09/025,521 for three months, to and including November 8, 2000. If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: November 8, 2000


Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

James DeCamp
Reg. No. 43,580

09709201-110800